Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
17 Maio 2024 - 8:00AM
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today announced
upcoming scientific presentations at the Gordon Research Conference
on Chemotactic Cytokines and at EASL 2024, the Annual Congress of
the European Association for the Study of the Liver.
The presentations cover a range of topics, from new preclinical
studies further elucidating the roles of the soluble protein target
CCL24 and Chemomab’s CCL24 neutralizing antibody CM-101 in
fibro-inflammatory disease, to novel translational research
designed to support the ongoing clinical development of CM-101 for
primary sclerosing cholangitis, a rare and often fatal fibrotic
liver disease. The presentations will be made available and
described in greater detail post embargo.
Gordon Research Conference: Chemotactic
Cytokines - Portland, Maine, USA, June 2-7,
2024
Date: |
June 2-7,
2024 |
Format: |
Poster presentation: Attenuating liver fibrosis and
inflammation: blocking CCL24 inhibits |
|
recruitment of hepatic stellate cells, monocytes and
neutrophils and modulates hepatic |
|
stellate cell activation |
Presenter: |
Prof. Amnon Peled, Hadassah University Hospital; Faculty of
Medicine, Hebrew University |
Information: |
2024 Chemotactic Cytokines Conference GRC |
|
|
EASL Congress 2024 – Milan, Italy, June 5-8,
2024
Date: |
June 6,
2024 |
Time: |
8:30-18:00 CEST |
Format: |
Poster presentation: Ex-vivo translational assay of hepatic
stellate cells using patient- |
|
derived serum characterizes the anti-fibrotic activity of
CM-101 |
Presenter: |
Revital Aricha, PhD, Vice President, Translational Science,
Chemomab Therapeutics |
Session: |
Poster - Fibrosis/Stellate cell biology, Abstract #380 |
|
|
Date: |
June 6, 2024 |
Time: |
8:30-17:00 CEST |
Format: |
Poster presentation: Machine learning-driven identification of
serum protein signature for |
|
primary sclerosing cholangitis and enhanced liver fibrosis
score |
Presenter: |
Ilan Vaknin, PhD, Vice President, R&D, Chemomab
Therapeutics |
Session: |
Immune-mediated and cholestatic: Experimental and
pathophysiology, Abstract #1032 |
|
|
Date: |
June 7, 2024 |
Time: |
12:25-13:45 CEST |
Format: |
Poster Tour: Ex-vivo translational assay of hepatic stellate
cells using patient-derived serum |
|
characterizes the anti-fibrotic activity of CM-101 |
Presenter: |
Ilan Vaknin, PhD, Vice President, R&D, Chemomab
Therapeutics |
Session: |
Fibrosis/Stellate Cell Biology Poster Tour, Abstract #380 |
Location: |
Basic Science Track Hub |
Information: |
EASL Congress 2024 |
|
|
In addition, Chemomab Corporate Development will be in San Diego
June 3-6, 2024, participating in the BIO International
Convention’s One-on-One Partnering™ event. Registered
attendees can click here to log in and schedule a meeting with
Chemomab.
About Chemomab Therapeutics Ltd.Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab’s CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready with an open U.S. IND. For
more information about Chemomab, visit chemomab.com.
Contacts:
Media & Investors:Chemomab
TherapeuticsBarbara LindheimConsulting Vice PresidentInvestor &
Public Relations, Strategic CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.com IR@chemomab.com
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024